A Phase 2 interventional study of Multivalent and 13vPnC in Pneumococcal Infections, sponsored by Pfizer. Completed at 39 sites in United States. Open to participants aged 42 Days to 98 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-02.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Pneumococcal Infections by Pfizer — 4 open to participants now, 8 under way, 5 of them phase 3. Pneumococcal Infections · Pfizer.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 34th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2018, is one of 7 in phase 2, and was the 41st registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →4 of the 75 studies in Pneumococcal Infections by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Pfizer · Sites in United States, Finland, Poland and 1 more country
Ages 15 mo–17 yrs · Healthy volunteers
Pfizer · Sites in United States, Japan, Puerto Rico
Ages 42 days–211 days · Healthy volunteers
Pfizer · Sites in United States, Argentina, Australia and 8 more countries
Ages 42 days–98 days · Healthy volunteers
By country, each count listing its studies:
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 98 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 9 · Phase 3 33 · Phase 4 7
First in 2001; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 570 across the 57 interventional studies, 1,050 across the 18 observational. Of the 67 that completed or were terminated, 45 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Pneumococcal Infections by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07794748Phase 3PfizerA Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults | 2027-04-26 |
| NCT06622109PfizerA Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months | 2026-12-04 |
| NCT06524414PfizerA Study to Learn About How a New Pneumococcal Vaccine Works in Infants | 2027-03-04 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Pneumococcal Infections by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 2, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Infants
NOTE: Detailed description has not been entered.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccines
Biological: Multivalent
13vPnC
Biological: 13vPnC
Pneumococcal conjugate vaccine
Also known as: Pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 3
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 days after Vaccination 3
Percentage of Participants With Local Reactions Within 7 Days After Vaccination 4
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
Time frame: Within 7 days after Vaccination 4
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
Time frame: Within 7 days after Vaccination 1
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
Time frame: Within 7 days after Vaccination 2
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 3
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
Time frame: Within 7 days after Vaccination 3
Percentage of Participants With Systemic Events Within 7 Days After Vaccination 4
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
Time frame: Within 7 days after Vaccination 4
Percentage of Participants With Adverse Events (AEs) From Vaccination 1 to 1 Month After Vaccination 3
An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship.
Time frame: From Vaccination 1 to 1 month after Vaccination 3 (up to 5 months)
Percentage of Participants With Adverse Events (AEs) From Vaccination 4 to 1 Month After Vaccination 4
An AE was any untoward medical occurrence in study participant who received study vaccine without regard to possibility of causal relationship.
Time frame: From Vaccination 4 to 1 month after Vaccination 4
Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 to 6 Months Following Vaccination 4
An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.
Time frame: From Vaccination 1 to 6 months after Vaccination 4 (up to 16 months)
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination 1 to 6 Months Following Vaccination 4
An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or is otherwise long-lasting in its effects.
Time frame: From Vaccination 1 to 6 months after Vaccination 4 (duration of 16 months)
Percentage of Participants Who Achieved Pre-specified Level of Pneumococcal IgG Concentrations Within 1 Month After Vaccination 3
Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per milliliter, for serotype 5: \>=0.23 microgram per milliliter, for serotype 6B: \>=0.10 microgram per milliliter and for serotype 19A: \>=0.12 microgram per milliliter.
Time frame: 1 month after Vaccination 3
Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) at 1 Month After Vaccination 3
IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
Time frame: 1 month after Vaccination 3
Pneumococcal Serotype-specific IgG GMCs at 1 Month After Vaccination 4
IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
Time frame: 1 Month after Vaccination 4
Participants were enrolled from 16 April 2018 to 11 February 2020 in the United States.
| Milestone | 20vPnC | 13vPnC |
|---|---|---|
| Started | 232 | 228 |
| Vaccination 1 | 231 | 227 |
| Vaccination 2 | 222 | 213 |
| Vaccination 3 | 210 | 206 |
| Vaccination 4 | 197 | 194 |
| Completed | 191 | 185 |
| Not completed | 41 | 43 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 12 | 15 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Protocol violation | 6 | 4 |
| Withdrew: Medication error without associated adverse event | 1 | 0 |
| Withdrew: No longer met eligibility criteria | 5 | 2 |
| Withdrew: Withdrawal by parent/guardian | 14 | 18 |
| Withdrew: Other | 1 | 1 |
| Withdrew: Randomized but not treated | 1 | 1 |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (0.5 to 2.0 centimeter \[cm\]), moderate (greater than \[\>\] 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 24.9 (19.4 to 31.0) | 25.4 (19.9 to 31.7) |
| Redness: Mild | 22.3 (17.1 to 28.2) | 23.7 (18.3 to 29.8) |
| Redness: Moderate | 2.6 (1.0 to 5.6) | 1.8 (0.5 to 4.5) |
| Redness: Severe | 0 (0.0 to 1.6) | 0 (0.0 to 1.6) |
| Swelling: Any | 12.7 (8.6 to 17.7) | 14.3 (10.0 to 19.6) |
| Swelling: Mild | 10.0 (6.5 to 14.7) | 12.9 (8.8 to 18.1) |
| Swelling: Moderate | 2.2 (0.7 to 5.0) | 1.3 (0.3 to 3.9) |
| Swelling: Severe | 0.4 (0.0 to 2.4) | 0 (0.0 to 1.6) |
| Pain at the injection site: Any | 51.1 (44.4 to 57.7) | 53.6 (46.8 to 60.2) |
| Pain at the injection site: Mild | 32.3 (26.3 to 38.8) | 35.7 (29.4 to 42.4) |
| Pain at the injection site: Moderate | 18.3 (13.5 to 24.0) | 17.9 (13.1 to 23.5) |
| Pain at the injection site: Severe | 0.4 (0.0 to 2.4) | 0 (0.0 to 1.6) |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 24.7 (19.0 to 31.0) | 28.4 (22.4 to 35.2) |
| Redness: Mild | 21.9 (16.5 to 28.0) | 24.0 (18.3 to 30.5) |
| Redness: Moderate | 2.8 (1.0 to 6.0) | 4.4 (2.0 to 8.20) |
| Redness: Severe | 0 (0.0 to 1.7) | 0 (0.0 to 1.8) |
| Swelling: Any | 16.3 (11.6 to 21.9) | 18.6 (13.5 to 24.7) |
| Swelling: Mild | 12.6 (8.4 to 17.7) | 13.2 (8.9 to 18.7) |
| Swelling: Moderate | 3.7 (1.6 to 7.2) | 5.4 (2.7 to 9.4) |
| Swelling: Severe | 0 (0.0 to 1.7) | 0 (0.0 to 1.8) |
| Pain at the injection site: Any | 42.8 (36.1 to 49.7) | 48.5 (41.5 to 55.6) |
| Pain at the injection site: Mild | 26.0 (20.3 to 32.5) | 28.9 (22.8 to 35.7) |
| Pain at the injection site: Moderate | 15.8 (11.2 to 21.4) | 19.6 (14.4 to 25.7) |
| Pain at the injection site: Severe | 0.9 (0.1 to 3.3) | 0 (0.0 to 1.8) |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 26.9 (20.9 to 33.6) | 26.5 (20.6 to 33.1) |
| Redness: Mild | 26.4 (20.4 to 33.0) | 23.0 (17.4 to 29.4) |
| Redness: Moderate | 0.5 (0.0 to 2.7) | 3.4 (1.4 to 6.9) |
| Redness: Severe | 0 (0.0 to 1.8) | 0 (0.0 to 1.8) |
| Swelling: Any | 17.9 (12.9 to 23.9) | 19.6 (14.4 to 25.7) |
| Swelling: Mild | 16.9 (12.0 to 22.8) | 15.7 (11.0 to 21.4) |
| Swelling: Moderate | 1.0 (0.1 to 3.5) | 3.4 (1.4 to 6.9) |
| Swelling: Severe | 0 (0.0 to 1.8) | 0.5 (0.0 to 2.7) |
| Pain at the injection site: Any | 44.3 (37.3 to 51.4) | 40.7 (33.9 to 47.8) |
| Pain at the injection site: Mild | 28.9 (22.7 to 35.6) | 27.9 (21.9 to 34.6) |
| Pain at the injection site: Moderate | 14.9 (10.3 to 20.6) | 12.7 (8.5 to 18.1) |
| Pain at the injection site: Severe | 0.5 (0.0 to 2.7) | 0 (0.0 to 1.8) |
Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (0.5 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Redness: Any | 25.8 (19.7 to 32.7) | 30.3 (23.7 to 37.4) |
| Redness: Mild | 24.2 (18.2 to 31.0) | 25.4 (19.3 to 32.3) |
| Redness: Moderate | 1.6 (0.3 to 4.6) | 4.9 (2.2 to 9.0) |
| Redness: Severe | 0 (0.0 to 2.0) | 0 (0.0 to 2.0) |
| Swelling: Any | 17.2 (12.1 to 23.4) | 14.1 (9.4 to 19.9) |
| Swelling: Mild | 15.1 (10.2 to 21.0) | 12.4 (8.0 to 18.1) |
| Swelling: Moderate | 2.2 (0.6 to 5.4) | 1.6 (0.3 to 4.7) |
| Swelling: Severe | 0 (0.0 to 2.0) | 0 (0.0 to 2.0) |
| Pain at the injection site: Any | 35.5 (28.6 to 42.8) | 35.7 (28.8 to 43.0) |
| Pain at the injection site: Mild | 26.9 (20.7 to 33.9) | 28.6 (22.3 to 35.7) |
| Pain at the injection site: Moderate | 8.6 (5.0 to 13.6) | 7.0 (3.8 to 11.7) |
| Pain at the injection site: Severe | 0 (0.0 to 2.0) | 0 (0.0 to 2.0) |
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 14.4 (10.1 to 19.6) | 9.8 (6.3 to 14.5) |
| Fever: >=38.0 degree C to 38.4 degree C | 10.0 (6.5 to 14.7) | 6.3 (3.5 to 10.3) |
| Fever: >38.4 degree C to 38.9 degree C | 3.9 (1.8 to 7.3) | 2.2 (0.7 to 5.1) |
| Fever: >38.9 degree C to 40.0 degree C | 0.4 (0.0 to 2.4) | 1.3 (0.3 to 3.9) |
| Fever: >40.0 degree C | 0 (0.0 to 1.6) | 0 (0.0 to 1.6) |
| Decreased appetite: Any | 25.3 (19.8 to 31.5) | 30.4 (24.4 to 36.8) |
| Decreased appetite: Mild | 16.2 (11.6 to 21.6) | 19.2 (14.3 to 25.0) |
| Decreased appetite: Moderate | 9.2 (5.8 to 13.7) | 10.7 (7.0 to 15.5) |
| Decreased appetite: Severe | 0 (0.0 to 1.6) | 0.4 (0.0 to 2.5) |
| Drowsiness: Any | 68.1 (61.7 to 74.1) | 71.0 (64.6 to 76.8) |
| Drowsiness: Mild | 51.1 (44.4 to 57.7) | 54.9 (48.1 to 61.5) |
| Drowsiness: Moderate | 16.6 (12.0 to 22.1) | 14.3 (10.0 to 19.6) |
| Drowsiness: Severe | 0.4 (0.0 to 2.4) | 1.8 (0.5 to 4.5) |
| Irritability: Any | 79.5 (73.7 to 84.5) | 77.7 (71.7 to 83.0) |
| Irritability: Mild | 23.6 (18.2 to 29.6) | 25.9 (20.3 to 32.1) |
| Irritability: Moderate | 50.7 (44.0 to 57.3) | 47.3 (40.6 to 54.1) |
| Irritability: Severe | 5.2 (2.7 to 9.0) | 4.5 (2.2 to 8.1) |
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 17.2 (12.4 to 22.9) | 23.0 (17.4 to 29.4) |
| Fever: >=38.0 degree C to 38.4 degree C | 10.2 (6.5 to 15.1) | 12.7 (8.5 to 18.1) |
| Fever: >38.4 degree C to 38.9 degree C | 4.2 (1.9 to 7.8) | 7.8 (4.5 to 12.4) |
| Fever: >38.9 degree C to 40.0 degree C | 2.8 (1.0 to 6.0) | 2.5 (0.8 to 5.6) |
| Fever: >40.0 degree C | 0 (0.0 to 1.7) | 0 (0.0 to 1.8) |
| Decreased appetite: Any | 23.3 (17.8 to 29.5) | 27.0 (21.0 to 33.6) |
| Decreased appetite: Mild | 14.4 (10.0 to 19.8) | 14.7 (10.1 to 20.3) |
| Decreased appetite: Moderate | 7.9 (4.7 to 12.4) | 11.8 (7.7 to 17.0) |
| Decreased appetite: Severe | 0.9 (0.1 to 3.3) | 0.5 (0.0 to 2.7) |
| Drowsiness: Any | 57.2 (50.3 to 63.9) | 56.4 (49.3 to 63.3) |
| Drowsiness: Mild | 37.2 (30.7 to 44.0) | 37.7 (31.1 to 44.8) |
| Drowsiness: Moderate | 17.7 (12.8 to 23.4) | 16.7 (11.8 to 22.5) |
| Drowsiness: Severe | 2.3 (0.8 to 5.3) | 2.0 (0.5 to 4.9) |
| Irritability: Any | 71.2 (64.6 to 77.1) | 79.9 (73.7 to 85.2) |
| Irritability: Mild | 20.0 (14.9 to 26.0) | 22.5 (17.0 to 28.9) |
| Irritability: Moderate | 48.8 (42.0 to 55.7) | 52.5 (45.4 to 59.5) |
| Irritability: Severe | 2.3 (0.8 to 5.3) | 4.9 (2.4 to 8.8) |
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 17.9 (12.9 to 23.9) | 18.1 (13.1 to 24.1) |
| Fever: >=38.0 degree C to 38.4 degree C | 10.0 (6.2 to 14.9) | 9.8 (6.1 to 14.7) |
| Fever: >38.4 degree C to 38.9 degree C | 4.5 (2.1 to 8.3) | 4.9 (2.4 to 8.8) |
| Fever: >38.9 degree C to 40.0 degree C | 3.5 (1.4 to 7.0) | 3.4 (1.4 to 6.9) |
| Fever: >40.0 degree C | 0 (0.0 to 1.8) | 0 (0.0 to 1.8) |
| Decreased appetite: Any | 30.8 (24.5 to 37.7) | 33.3 (26.9 to 40.3) |
| Decreased appetite: Mild | 20.9 (15.5 to 27.2) | 19.1 (14.0 to 25.2) |
| Decreased appetite: Moderate | 9.5 (5.8 to 14.4) | 13.7 (9.3 to 19.2) |
| Decreased appetite: Severe | 0.5 (0.0 to 2.7) | 0.5 (0.0 to 2.7) |
| Drowsiness: Any | 41.3 (34.4 to 48.4) | 45.6 (38.6 to 52.7) |
| Drowsiness: Mild | 28.9 (22.7 to 35.6) | 29.9 (23.7 to 36.7) |
| Drowsiness: Moderate | 11.4 (7.4 to 16.7) | 15.7 (11.0 to 21.4) |
| Drowsiness: Severe | 1.0 (0.1 to 3.5) | 0 (0.0 to 1.8) |
| Irritability: Any | 72.6 (65.9 to 78.7) | 69.6 (62.8 to 75.8) |
| Irritability: Mild | 28.9 (22.7 to 35.6) | 27.5 (21.5 to 34.1) |
| Irritability: Moderate | 40.8 (33.9 to 47.9) | 37.7 (31.1 to 44.8) |
| Irritability: Severe | 3.0 (1.1 to 6.4) | 4.4 (2.0 to 8.2) |
Systemic events included fever, decreased appetite, drowsiness, irritability and were recorded by using an electronic diary. Fever was defined as \>= 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabled, not interested in usual daily activity). Irritability was graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable; crying could not be comforted).
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Fever: >=38.0 degree C | 12.4 (8.0 to 18.0) | 14.6 (9.8 to 20.5) |
| Fever: >=38.0 degree C to 38.4 degree C | 5.9 (3.0 to 10.3) | 4.3 (1.9 to 8.3) |
| Fever: >38.4 degree C to 38.9 degree C | 3.2 (1.2 to 6.9) | 7.0 (3.8 to 11.7) |
| Fever: >38.9 degree C to 40.0 degree C | 3.2 (1.2 to 6.9) | 3.2 (1.2 to 6.9) |
| Fever: >40.0 degree C | 0 (0.0 to 2.0) | 0 (0.0 to 2.0) |
| Decreased appetite: Any | 23.7 (17.7 to 30.4) | 29.2 (22.8 to 36.3) |
| Decreased appetite: Mild | 13.4 (8.9 to 19.2) | 15.7 (10.8 to 21.7) |
| Decreased appetite: Moderate | 10.2 (6.3 to 15.5) | 13.5 (8.9 to 19.3) |
| Decreased appetite: Severe | 0 (0.0 to 2.0) | 0 (0.0 to 2.0) |
| Drowsiness: Any | 32.8 (26.1 to 40.0) | 37.3 (30.3 to 44.7) |
| Drowsiness: Mild | 26.9 (20.7 to 33.9) | 25.4 (19.3 to 32.3) |
| Drowsiness: Moderate | 4.8 (2.2 to 9.0) | 11.9 (7.6 to 17.4) |
| Drowsiness: Severe | 1.1 (0.1 to 3.8) | 0 (0.0 to 2.0) |
| Irritability: Any | 62.4 (55.0 to 69.3) | 62.7 (55.3 to 69.7) |
| Irritability: Mild | 23.7 (17.7 to 30.4) | 19.5 (14.0 to 25.9) |
| Irritability: Moderate | 36.0 (29.1 to 43.4) | 40.0 (32.9 to 47.4) |
| Irritability: Severe | 2.7 (0.9 to 6.2) | 3.2 (1.2 to 6.9) |
An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Vaccination 1 to 1 Month After Vaccination 3 | 61.0 (54.4 to 67.4) | 56.4 (49.7 to 62.9) |
An AE was any untoward medical occurrence in study participant who received study vaccine without regard to possibility of causal relationship.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Vaccination 4 to 1 Month After Vaccination 4 | 18.3 (13.1 to 24.4) | 25.3 (19.3 to 32.0) |
An SAE is any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Vaccination 1 to 6 Months Following Vaccination 4 | 5.2 (2.7 to 8.9) | 2.2 (0.7 to 5.1) |
An NDCMC is defined as a disease or medical condition, not previously identified, that is expected to be persistent or is otherwise long-lasting in its effects.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Vaccination 1 to 6 Months Following Vaccination 4 | 5.2 (2.7 to 8.9) | 3.5 (1.5 to 6.8) |
Pre-specified levels of serotypes were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per milliliter, for serotype 5: \>=0.23 microgram per milliliter, for serotype 6B: \>=0.10 microgram per milliliter and for serotype 19A: \>=0.12 microgram per milliliter.
| percentage of participants | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 87.8 (82.3 to 92.1) | 87.7 (82.1 to 92.0) |
| Serotype 3 | 65.1 (57.8 to 71.9) | 75.4 (68.6 to 81.4) |
| Serotype 4 | 87.8 (82.3 to 92.1) | 91.4 (86.5 to 95.0) |
| Serotype 5 | 87.8 (82.3 to 92.1) | 89.8 (84.6 to 93.8) |
| Serotype 6A | 93.7 (89.2 to 96.7) | 92.5 (87.8 to 95.8) |
| Serotype 6B | 86.8 (81.1 to 91.3) | 90.4 (85.2 to 94.2) |
| Serotype 7F | 98.9 (96.2 to 99.9) | 97.9 (94.6 to 99.4) |
| Serotype 9V | 89.4 (84.1 to 93.4) | 89.3 (84.0 to 93.3) |
| Serotype 14 | 94.2 (89.8 to 97.1) | 95.7 (91.7 to 98.1) |
| Serotype 18C | 92.6 (87.9 to 95.9) | 95.2 (91.1 to 97.8) |
| Serotype 19A | 98.4 (95.4 to 99.7) | 97.9 (94.6 to 99.4) |
| Serotype 19F | 98.4 (95.4 to 99.7) | 96.8 (93.1 to 98.8) |
| Serotype 23F | 79.9 (73.5 to 85.4) | 81.8 (75.5 to 87.1) |
| Serotype 8 | 99.5 (97.1 to 100.0) | 3.7 (1.5 to 7.6) |
| Serotype 10A | 87.8 (82.3 to 92.1) | 1.1 (0.1 to 3.8) |
| Serotype 11A | 97.4 (93.9 to 99.1) | 1.6 (0.3 to 4.6) |
| Serotype 12F | 82.5 (76.4 to 87.7) | 0.5 (0.0 to 2.9) |
| Serotype 15B | 98.9 (96.2 to 99.9) | 4.3 (1.9 to 8.3) |
| Serotype 22F | 98.9 (96.2 to 99.9) | 1.1 (0.1 to 3.8) |
| Serotype 33F | 92.1 (87.2 to 95.5) | 1.6 (0.3 to 4.6) |
IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
| microgram per milliliter | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 0.92 (0.81 to 1.05) | 1.16 (1.00 to 1.33) |
| Serotype 3 | 0.43 (0.38 to 0.48) | 0.56 (0.49 to 0.64) |
| Serotype 4 | 1.36 (1.16 to 1.61) | 1.64 (1.39 to 1.93) |
| Serotype 5 | 0.93 (0.79 to 1.11) | 1.13 (0.96 to 1.34) |
| Serotype 6A | 2.28 (1.94 to 2.67) | 2.57 (2.16 to 3.05) |
| Serotype 6B | 0.63 (0.49 to 0.80) | 0.99 (0.77 to 1.27) |
| Serotype 7F | 2.15 (1.92 to 2.40) | 2.59 (2.28 to 2.93) |
| Serotype 9V | 1.22 (1.05 to 1.42) | 1.45 (1.24 to 1.70) |
| Serotype 14 | 3.15 (2.69 to 3.70) | 3.60 (3.07 to 4.21) |
| Serotype 18C | 1.59 (1.37 to 1.84) | 2.05 (1.76 to 2.38) |
| Serotype 19A | 0.85 (0.74 to 0.96) | 1.02 (0.89 to 1.17) |
| Serotype 19F | 1.98 (1.76 to 2.22) | 2.28 (1.99 to 2.61) |
| Serotype 23F | 0.94 (0.78 to 1.14) | 1.26 (1.03 to 1.55) |
| Serotype 8 | 2.09 (1.90 to 2.30) | 0.04 (0.03 to 0.04) |
| Serotype 10A | 1.67 (1.35 to 2.08) | 0.03 (0.03 to 0.03) |
| Serotype 11A | 1.94 (1.70 to 2.21) | 0.01 (0.01 to 0.01) |
| Serotype 12F | 0.86 (0.72 to 1.01) | 0.02 (0.02 to 0.02) |
| Serotype 15B | 5.86 (5.11 to 6.72) | 0.04 (0.04 to 0.05) |
| Serotype 22F | 4.62 (3.99 to 5.35) | 0.01 (0.01 to 0.01) |
| Serotype 33F | 2.21 (1.87 to 2.61) | 0.05 (0.04 to 0.05) |
IgG GMCs were determined for each of the 20 pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
| microgram per milliliter | 20vPnC | 13vPnC |
|---|---|---|
| Serotype 1 | 2.65 (2.33 to 3.02) | 3.63 (3.20 to 4.11) |
| Serotype 3 | 1.15 (0.97 to 1.35) | 1.49 (1.28 to 1.74) |
| Serotype 4 | 7.16 (6.22 to 8.24) | 9.45 (8.16 to 10.95) |
| Serotype 5 | 3.41 (2.95 to 3.93) | 4.95 (4.29 to 5.71) |
| Serotype 6A | 13.77 (12.16 to 15.59) | 18.83 (16.39 to 21.63) |
| Serotype 6B | 6.37 (5.42 to 7.50) | 9.73 (8.13 to 11.65) |
| Serotype 7F | 6.14 (5.51 to 6.83) | 9.32 (8.26 to 10.52) |
| Serotype 9V | 5.52 (4.82 to 6.31) | 7.78 (6.77 to 8.95) |
| Serotype 14 | 8.61 (7.32 to 10.12) | 11.04 (9.44 to 12.90) |
| Serotype 18C | 5.58 (4.89 to 6.36) | 8.46 (7.25 to 9.88) |
| Serotype 19A | 5.71 (4.91 to 6.64) | 7.05 (6.04 to 8.24) |
| Serotype 19F | 7.79 (6.73 to 9.01) | 9.30 (7.99 to 10.83) |
| Serotype 23F | 6.06 (5.16 to 7.12) | 9.81 (8.10 to 11.88) |
| Serotype 8 | 3.12 (2.78 to 3.49) | 0.05 (0.04 to 0.06) |
| Serotype 10A | 9.93 (8.58 to 11.50) | 0.03 (0.03 to 0.04) |
| Serotype 11A | 5.70 (4.96 to 6.54) | 0.01 (0.01 to 0.02) |
| Serotype 12F | 1.92 (1.68 to 2.20) | 0.02 (0.02 to 0.03) |
| Serotype 15B | 18.45 (16.43 to 20.72) | 0.04 (0.04 to 0.05) |
| Serotype 22F | 14.68 (12.62 to 17.08) | 0.01 (0.01 to 0.01) |
| Serotype 33F | 4.70 (4.20 to 5.27) | 0.05 (0.04 to 0.05) |
Collected over Local reactions and Systemic events: within 7 days after each vaccination (systematic assessment), Non serious AEs: Vaccination 1 to 1 month after Vaccination 3 (up to 5 months) and Vaccination 4 to 1 month after Vaccination 4, SAEs: up to 16 months after Vaccination 1. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20vPnC | 0/231 (0%) | 12/231 (5.2%) | 225/231 (97.4%) |
| 13vPnC | 0/227 (0%) | 5/227 (2.2%) | 224/227 (98.7%) |
| Event | 20vPnC | 13vPnC |
|---|---|---|
| GastroenteritisInfections and infestations | 1/231 | 1/227 |
| Parainfluenzae virus infectionInfections and infestations | 0/231 | 1/227 |
| PneumoniaInfections and infestations | 0/231 | 1/227 |
| Respiratory syncytial virus infectionInfections and infestations | 0/231 | 1/227 |
| Seizure like phenomenaNervous system disorders | 0/231 | 1/227 |
| AnaemiaBlood and lymphatic system disorders | 1/231 | 0/227 |
| BronchiolitisInfections and infestations | 1/231 | 0/227 |
| Bronchitis viralInfections and infestations | 1/231 | 0/227 |
| Croup infectiousInfections and infestations | 1/231 | 0/227 |
| Meningitis viralInfections and infestations | 1/231 | 0/227 |
| Event | 20vPnC | 13vPnC |
|---|---|---|
| Irritability (IRRITABILITY)Psychiatric disorders | 214/231 | 206/227 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 188/231 | 189/227 |
| Injection site pain (PAIN)General disorders | 163/231 | 167/227 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 134/231 | 136/227 |
| Injection site erythema (REDNESS)General disorders | 112/231 | 120/227 |
| Pyrexia (FEVER)General disorders | 90/231 | 90/227 |
| Injection site swelling (SWELLING)General disorders | 76/231 | 81/227 |
| Upper respiratory tract infectionInfections and infestations | 40/231 | 44/227 |
| Otitis mediaInfections and infestations | 25/231 | 21/227 |
| TeethingGastrointestinal disorders | 10/231 | 16/227 |
All randomized participants.
| Age, Continuous(days) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Mean | 64.5 ± 8.07 | 64.5 ± 6.68 | 64.5 ± 7.40 |
| Sex: Female, Male(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Female | 112 | 115 | 227 |
| Male | 120 | 113 | 233 |
| Ethnicity (NIH/OMB)(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| Hispanic or Latino | 41 | 40 | 81 |
| Not Hispanic or Latino | 191 | 188 | 379 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 20vPnC | 13vPnC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 3 | 7 |
| Asian | 9 | 5 | 14 |
| Native Hawaiian or Other Pacific Islander | 1 | 3 | 4 |
| Black or African American | 35 | 29 | 64 |
| White | 161 | 171 | 332 |
| More than one race | 22 | 15 | 37 |
| Unknown or Not Reported | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2018 to primary completion in Feb 2020, 21 months.
Results were first posted in Mar 2021, 1 year after primary completion.
Of 23 phase 2 interventional studies under Pneumococcal Infections, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 21 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal Conjugate Vaccine